Pharmaceuticals 2012, 5(9), 1021-1031; doi:10.3390/ph5091021
Review

Why and How the Old Neuroleptic Thioridazine Cures the XDR-TB Patient

1,* email and 2email
Received: 13 August 2012; in revised form: 10 September 2012 / Accepted: 11 September 2012 / Published: 17 September 2012
(This article belongs to the Special Issue Antituberculosis Drugs)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: This mini-review provides the entire experimental history of the development of the old neuroleptic thioridazine (TZ) for therapy of antibiotic resistant pulmonary tuberculosis infections. TZ is effective when used in combination with antibiotics to which the initial Mycobacterium tuberculosis was resistant. Under proper cardiac evaluation procedures, the use of TZ is safe and does not produce known cardiopathy such as prolongation of QT interval. Because TZ is cheap, it should be considered for therapy of XDR and TDR-Mtb patients in economically disadvantaged countries.
Keywords: pulmonary tuberculosis; thioridazine; in vitro activity; ex vivo activity; cures the mouse of MDR-Mtb infections; XDR-TB; TDR-TB; cures the human of an XDR-TB infection; mechanisms of action; inhibitor of efflux pumps; enhances killing of intracellular Mtb
PDF Full-text Download PDF Full-Text [200 KB, uploaded 18 September 2012 15:23 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Amaral, L.; Molnar, J. Why and How the Old Neuroleptic Thioridazine Cures the XDR-TB Patient. Pharmaceuticals 2012, 5, 1021-1031.

AMA Style

Amaral L, Molnar J. Why and How the Old Neuroleptic Thioridazine Cures the XDR-TB Patient. Pharmaceuticals. 2012; 5(9):1021-1031.

Chicago/Turabian Style

Amaral, Leonard; Molnar, Joseph. 2012. "Why and How the Old Neuroleptic Thioridazine Cures the XDR-TB Patient." Pharmaceuticals 5, no. 9: 1021-1031.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert